Enveric Biosciences (ENVB) Profit After Tax (2010 - 2026)
Enveric Biosciences (ENVB) posted Profit After Tax of -$1.6 million for Q1 2026, up 25.23% sequentially from -$2.2 million in Q4 2025, and up 24.92% YoY from -$1.3 million in Q1 2025.
Enveric Biosciences (ENVB) Profit After Tax (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Profit After Tax for 17 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Profit After Tax rose 24.92% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 11.83% YoY) and the FY2025 annual result came in at -$8.8 million, up 8.62% from the prior year.
- Profit After Tax climbed to -$1.6 million in Q1 2026 per ENVB's latest filing, from -$2.2 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$1.6 million in Q1 2026 and troughed at -$7.9 million in Q4 2022.
- A 5-year average of -$3.3 million and a median of -$2.8 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2024: Profit After Tax slumped 207.23% in 2022, then surged 70.43% in 2024.
- Over 5 years, Profit After Tax stood at -$7.9 million in 2022, then surged by 56.3% to -$3.4 million in 2023, then gained by 6.45% to -$3.2 million in 2024, then surged by 31.73% to -$2.2 million in 2025, then gained by 25.23% to -$1.6 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$1.6 million, -$2.2 million, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | -3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.64 Mn |
| Dec 31, 2025 | -2.19 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.52 Mn |
| Mar 31, 2025 | -2.18 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Sep 30, 2024 | -2.05 Mn |
| Jun 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -2.46 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Sep 30, 2023 | -2.82 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Mar 31, 2023 | -4.68 Mn |
| Dec 31, 2022 | -7.86 Mn |
| Sep 30, 2022 | -3.02 Mn |
| Jun 30, 2022 | -2.79 Mn |
| Mar 31, 2022 | -4.52 Mn |
| Dec 31, 2021 | 33.56 Mn |
| Sep 30, 2021 | -2.71 Mn |
| Jun 30, 2021 | -908,289.00 |